Source: Health Canada shortage reports · Updated Sep 23, 2026
Some Gatifloxacin products are in shortage in Canada (1 of 3 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Nov 20, 2026.
A fluoroquinolone antibiotic used as eye drops to treat bacterial eye infections.
Products affected
1 / 3
In shortage since
Jan 23, 2026
Est. full return
Nov 20, 2026
Reports on file
10
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
JAMP GATIFLOXACIN
0.3% · SOLUTION · JAMP PHARMA CORPORATION
DIN 02533235 · since Jan 23, 2026, est. end Nov 20, 2026 · Disruption of the manufacture of the drug.
Resolved
APO-GATIFLOXACIN
0.3% · SOLUTION · APOTEX INC
DIN 02327260 · ended Sep 17, 2026 · Disruption of the manufacture of the drug.
Resolved
ZYMAR
0.3% · SOLUTION · ABBVIE CORPORATION
DIN 02257270 · ended May 8, 2026 · Demand increase for the drug.
Resolved
APO-GATIFLOXACIN
0.3% · SOLUTION · APOTEX INC
DIN 02327260 · ended Apr 11, 2024 · Disruption of the manufacture of the drug.
Resolved
ZYMAR
0.3% · SOLUTION · ABBVIE CORPORATION
DIN 02257270 · ended Dec 6, 2023 · Disruption of the manufacture of the drug.
Resolved
APO-GATIFLOXACIN
0.3% · SOLUTION · APOTEX INC
DIN 02327260 · ended Nov 23, 2023 · Disruption of the manufacture of the drug.
Resolved
ZYMAR
0.3% · SOLUTION · ABBVIE CORPORATION
DIN 02257270 · ended Oct 27, 2022 · Delay in shipping of the drug.
Resolved
ZYMAR
0.3% · SOLUTION · ALLERGAN INC
DIN 02257270 · ended Aug 18, 2021 · Disruption of the manufacture of the drug.
Resolved
ZYMAR
0.3% · SOLUTION · ALLERGAN INC
DIN 02257270 · ended Sep 18, 2019 · Disruption of the manufacture of the drug.
Resolved
ZYMAR
0.3% · SOLUTION · ALLERGAN INC
DIN 02257270 · ended Oct 6, 2017 · Disruption of the manufacture of the drug.
What's happening
Gatifloxacin is currently affected by an active shortage report filed with Health Canada by JAMP PHARMA CORPORATION.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Gatifloxacin is classified under “ANTIINFECTIVES” (ATC S01AE).
Recent changes
Sep 23, 2026
Estimated end date pushed back : Nov 15, 2026 → Nov 20, 2026
Sep 18, 2026
Shortage resolved
Sep 11, 2026
Estimated end date pushed back : Sep 4, 2026 → Nov 15, 2026
Common questions
What is Gatifloxacin used for?
A fluoroquinolone antibiotic used as eye drops to treat bacterial eye infections.
When will Gatifloxacin be back in stock in Canada?
The latest manufacturer estimate is Nov 20, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Gatifloxacin in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Possible alternatives in the same class (antiinfectives)
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.